Skip to main content
KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL). Nastoupil, L. J., Dahiya, S., Miklos, D., Reagan, P., Ulrickson, M., Jung, A., Kloos, I., Dong, J., Chou, J., Murakami, J., Rodriguez, K., Nahas, M. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for Web of Science ID 000863680305078